MA-ASTADIA
23.3.2021 15:02:11 CET | Business Wire | Press release
In today’s environment, many organizations have a “Cloud First” strategy for deploying business applications. Since most of the important business applications reside on mainframes, moving these applications and databases to any Cloud platform requires expert skills and technology.
The combination of Astadia’s Replatforming solutions, plus the Anubex Refactoring capabilities, offers a complete mainframe migration RoadMap. Astadia now offers all solution sets required to migrate from any IBM Z Series, or Unisys ClearPath platform, to the Cloud platform of their choosing.
“This is an exciting time to be in the Mainframe Migration business. The rapidly shrinking pool of people with mainframe software and hardware skills has given a new sense of urgency to IT buyers. The shortage of these critical skills is exacerbated by the COVID-19 Pandemic,” said Scott G. Silk, Chairman and CEO of Astadia.
“With this wave of Cloud computing, organizations are rapidly moving their applications and databases from mainframes. The Cloud enables incredible software innovation and developer productivity, access to AI and Predictive Analytics, while only charging the client for the resources they consume,” said Mr. Silk.
“Combining the forces of Astadia and Anubex leads to a unique combination of sales and delivery power with an exceptional portfolio of solutions for the migration market. This team is ready to accompany the largest organizations on their journey to the Cloud and becomes an important player in the top tier of mainframe migration companies,” said Louis Heymans, Managing Director of Anubex.
The acquisition of Anubex by Astadia allows the Anubex R&D team to continue to focus on extending their portfolio of products (CodeTurn, DataTurn, TestMatch and DataMatch) to automate refactoring and testing of legacy systems. The development of these products started well over 20 years ago, and today includes legacy technologies such as Assembler, COBOL, IDMS and Natural ADABAS that can be migrated to, among others, Java or C# in combination with all the leading SQL-databases – with the resulting applications ready for deployment in the (public) Cloud. These solutions using a Cloud-based “Migration Factory” model will be available to Astadia partners and clients worldwide.
For more details, take advantage of Astadia’s FREE Mainframe-to-Cloud Modernization Guide series, where we assist our clients as they plan and move into a safe and secure, high performance, cloud environment. This series covers IBM (NYSE:IBM) and UNISYS (NYSE:UIS) mainframes, and all popular target Cloud Platforms.
In these Mainframe-to-Cloud Migration Guides , readers will explore 20 pages of:
- Why migrate mainframe applications & databases to the Cloud?
- The challenges associated with mainframe modernization
- Detailed diagrams of mainframe software mappings to Cloud Platforms
- Programming languages & database translation tables
The Mainframe-to-Cloud Guide series is FREE , and may be downloaded.
Click on this link to view the Astadia Mainframe-to-Cloud Modernization Guide Series.
For more information visit http://www.astadia.com and follow Astadia at @AstadiaInc , Facebook/AstadiaInc , LinkedIn/Astadia
About Anubex
Anubex is an industry leader providing core software solutions, know-how, and support for complex mainframe-to-cloud migration and modernization projects.
With over 25 years of experience, demonstrated solutions and high-performing software tools, we help enterprises and government organizations boost their innovation capacity, competitiveness and agility by accelerating their digital transformation.
We are migration specialists, independent of the legacy or target technology stack. Our core competence lies in the know-how, the unique software solutions, and the extensive experience in how complex migration projects should be undertaken: what the stages and steps are, how the project should be structured, what the typical pitfalls and risks are, and how processes should be automated.
Our automated conversion and testing tools , combined with an innovative migration methodology , enable our team to support complex modernization projects and be one of the most competitive and reliable migration companies in the world.
Contacts / Headquarters
www.anubex.com
Anubex HQ
Anubex NV
Veldkant 13
2550 Kontich
Belgium
+32 3 450 42 50
migrations@anubex.com
About Astadia
Astadia is the market leading mainframe modernization consulting and systems integration boutique. A worldwide IT consulting firm, we specialize in moving IBM and Unisys mainframe applications and databases to distributed and cloud platforms. In fact, we were recently named Microsoft’s Mainframe-to-Azure partner of the year. Clients select Astadia for the following reasons: mainframe to cloud market focus, 28 years of mainframe experience, and hybrid READI methodology. Upon project completion, customers often select Astadia to manage their cloud environment as well. We have successfully completed over 200 mainframe modernization projects and are recognized industrywide as the mainframe to cloud experts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom